TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells

Anticancer Research

Volumn 34, Issue 2, 2014, Pages 729-734

  Tang, Xiang Jun ^a   Lu, Jun Ti ^a   Tu, Han Jun ^a   Huang, Kuan Ming ^a   Fu, Rui ^a   Cao, Gang ^a   Huang, Min ^a   Cheng, Long Hai ^a   Dai, Long Jun ^a,b   Zhang, Li ^a  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cytotherapy; Gene therapy; Glioblastoma; Mesenchymal stem cells

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TNFSF10 PROTEIN, RAT;

ANIMAL EXPERIMENT; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL TYPE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; EXPRESSION VECTOR; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA CELL; IMMUNOBLOTTING; IN VITRO STUDY; MTT ASSAY; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BIOSYNTHESIS; BRAIN TUMOR; CYTOLOGY; CYTOTHERAPY; GENE THERAPY; GENETIC ENGINEERING; GENETICS; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; TRANSGENIC RAT;

CYTOTHERAPY; GENE THERAPY; GLIOBLASTOMA; MESENCHYMAL STEM CELLS;

ANIMALS; BRAIN NEOPLASMS; COCULTURE TECHNIQUES; GENETIC ENGINEERING; GLIOBLASTOMA; MESENCHYMAL STROMAL CELLS; RATS; RATS, TRANSGENIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION;

EID: 84897033264     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA and Cavenee WK: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710, 2007.
2. Ferguson SD: Malignant gliomas: diagnosis and treatment. Dis Mon 57: 558-569, 2011.
3. Westphal M and Lamszus K: The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci 12: 495-508, 2011.
4. Loebinger MR and Janes SM: Stem cells as vectors for antitumour therapy. Thorax 65: 362-369, 2010.
5. Dai LJ, Moniri MR, Zeng ZR, Zhou JX, Rayat J and Warnock GL: Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett 305: 8-20, 2011.
6. Sun XY, Nong J, Qin K, Warnock GL and Dai LJ: Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine. World J Stem Cells 3: 96-103, 2011.
7. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690, 1996.
8. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-382, 1995.
9. Wu GS: TRAIL as a target in anti-cancer therapy. Cancer Lett 285: 1-5, 2009.
10. Almasan A and Ashkenazi A: Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14: 337-348, 2003.
11. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
12. Ashkenazi A, Holland P and Eckhardt SG: Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26: 3621-3630, 2008.
13. Sun XY, Nong J, Qin K, Lu H, Moniri MR, Dai LJ and Warnock GL: MSC(TRAIL)-mediated HepG2 cell death in direct and indirect co-cultures. Anticancer Res 31: 3705-12, 2011.
14. Yang B, Wu X, Mao Y, Bao W, Gao L, Zhou P, Xie R, Zhou L and Zhu J: Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells. Neurosurgery 65: 610-624, 2009.
15. Kim SM, Kim DS, Jeong CH, Kim DH, Kim JH, Jeon HB, Kwon SJ, Jeun SS, Yang YS, Oh W and Chang JW: CXC chemokine receptor 1 enhances the ability of human umbilical cord blood-derived mesenchymal stem cells to migrate toward gliomas. Biochem Biophys Res Commun 407: 741-746, 2011.
16. Vogel S, Peters C, Etminan N, Borger V, Schimanski A, Sabel MC and Sorg RV: Migration of mesenchymal stem cells towards glioblastoma cells depends on hepatocyte-growth factor and is enhanced by aminolaevulinic acid-mediated photodynamic treatment. Biochem Biophys Res Commun 431: 428-432, 2013.
17. Kosaka H, Ichikawa T, Kurozumi K, Kambara H, Inoue S, Maruo T, Nakamura K, Hamada H and Date I: Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma. Cancer Gene Ther 19: 572-578, 2012.
18. Doucette T, Rao G, Yang Y, Gumin J, Shinojima N, Bekele BN, Qiao W, Zhang W and Lang FF: Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma model. Neoplasia 13: 716-725, 2011.
19. Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, Figueiredo JL, Martuza RL, Weissleder R and Shah K: Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 106: 4822-4827, 2009.
20. Moniri MR, Sun XY, Rayat J, Dai D, Ao Z, He Z, Verchere CB, Dai LJ and Warnock GL: TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther 19: 652-658, 2012.
21. Johnstone RW, Frew AJ and Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782-798, 2008.
22. Jeong M, Kwon YS, Park SH, Kim CY, Jeun SS, Song KW, Ko Y, Robbins PD, Billiar TR, Kim BM and Seol DW: Possible novel therapy for malignant gliomas with secretable trimeric TRAIL. PLoS One 4: e4545, 2009.
23. Xu J, Zhou JY, Wei WZ and Wu GS: Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 5: e10226, 2010.